Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Intestinal, adipose, and liver inflammation in diet-induced obese mice.
- H. Li, C. Lelliott, +7 authors E. Michaëlsson
- Metabolism: clinical and experimental
- 1 December 2008
Fat depots contiguous with intestine and their capacity for exaggerated inflammatory responses to conditions of impaired gut barrier function may account for the particularly pathogenic role of VAT in obesity-induced metabolic disorders. Expand
Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice
This study provides the first evidence that a Pnpla3 ASO therapy can improve all features of NAFLD, including liver fibrosis, and suppress the expression of a strong innate genetic risk factor, PnPla3 148M, which may open up a precision medicine approach in NASH. Expand
Differences in associations between HSD11B1 gene expression and metabolic parameters in subjects with and without impaired glucose homeostasis.
- C. Karlsson, M. Jernås, +5 authors B. Carlsson
- Diabetes research and clinical practice
- 1 June 2010
HSD11B1 mRNA levels are associated with metabolic parameters and anthropometric measurements and metabolic parameters in subjects with normal glucose homeostasis but not in Subjects with impaired glucoseHomeostasis. Expand
Plasminogen activator inhibitor-1 levels and activity decrease after intervention in patients with critical limb ischaemia.
- M. Björck, M. Lepkowska Eriksson, +5 authors B. Kragsterman
- European journal of vascular and endovascular…
- 1 August 2013
Endovascular and open surgical treatment resulted in improved ankle pressure and ABI and a transient increase in CRP and a sustained reduction in PAI-1 levels and activity. Expand
Effects of a novel potent melanin‐concentrating hormone receptor 1 antagonist, AZD1979, on body weight homeostasis in mice and dogs
- K. Ploj, L. Benthem, +12 authors D. Lindén
- Biology, Medicine
- British journal of pharmacology
- 1 September 2016
Two new drugs have been developed for the treatment of obesity and lower body weight in rodents and the mechanisms for the body weight loss and whether MCH1 receptor antagonism can lower bodyWeight in species expressing both MCH receptors are not fully understood. Expand
Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis
- B. Carlsson, D. Lindén, +4 authors R. Loomba
- Alimentary pharmacology & therapeutics
- 7 May 2020
Emerging data indicate that genetic susceptibility increases risks of NAFLD, NASH and NASH‐related cirrhosis. Expand
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
- E. Ekholm, L. Hansen, +4 authors B. Hirshberg
- Endocrine practice : official journal of the…
- 1 March 2017
Increased C-peptide to insulin ratio with saxagliptin + dapagliflozin and dapagslimlozin + placebo add-on to metforminCompared with baseline, the effects of these treatments on β-cell function improved, suggesting thatdapag liflozin increases insulin clearance and may contribute to lower circulating insulin. Expand
Effect of Tenapanor on Interdialytic Weight Gain in Patients on Hemodialysis.
- G. Block, D. Rosenbaum, +6 authors B. Carlsson
- Clinical journal of the American Society of…
- 7 September 2016
Tenapanor treatment increased stool sodium and weight over placebo in patients undergoing hemodialysis, but over 4 weeks of treatment, there was no difference in interdialytic weight gain between patients treated with tenapanor and those receiving placebo. Expand
Abstract 71: Assessment of Reverse Cholesterol Transport in Vivo in Humans: A Novel Method
Aim: Reverse cholesterol transport (RCT) is one of the main atheroprotective functions of HDL; however no method exists to assess RCT in vivo in humans. We developed a macrophage-specific method us...
Abstract 13307: An Oral Antisense Oligonucleotide for PCSK9 Inhibition in Humans
A highly potent, chemically modified PCSK9 antisense oligonucleotide (ASO) with potential for oral deliverence inoters is presented. Expand